Subject: Before the Bell: (TDST) Enabling Modern Medicine.

From: "The Savvy Investor" <[email-masked]>
Date: Tue, 27 Jan 2004 08:56:00 -0600

October
2003 Edition of The Savvy Investor

Each
month The Savvy Investor analysts study, research, and examine
hundreds of stocks, in an effort to pinpoint the one with
the most promise.

Special Edition Pick : TDS Telemedicine, Inc.

Symbol: TDST

Recent
Trading Range: $.10

Opinion: Strong
Buy

In
Related News:

Health
care providers are getting wired up for a future where every
patient's medical record is a click away and doctors assist
one another in operations thousands of miles apart via video
conferencing. More...

A
new approach to healthcare around the globe is on its way,
according to experts at the World Economic Forum.. More....

TDS
Telemedicine CEO Roger Coomber and Chief Medical Officer
Keith Freeman Interviewed. Video

Financial
Analysis

With
funding approval in place, as well as anticipated additional
equity funding over the next few months, TDS expects the
following financial performance:

2003 Revenues $1.0 million

Net Pre-tax $100,000

2004 Revenues $13.5 million

Net Pre-tax $3.4 million

2005 Revenues $22.0 million

Net Pre-tax $6.25 million

Pechala's reports indicate
TDST stock

will appreciate +35% for the next 2-week

period. (see
PDF)

Corporate
Snapshot

TDS Telemedicine Inc is the
parent Company of an established UK based firm,
TDS Dermatology Ltd.  For the past 5 years this
Company has provided comprehensive dermatology
telemedicine to the National Health Service in
England. Over 25,000 telemedical
consultations have been performed since the Company
commenced operations, making it the world's largest
telemedical dermatology provider.

Now utilizing
telemedical technology, a single health care
professional can see multiple patients in almost any
location, even in the patients' homes. This means
maximum productivity for medical personnel, lower
capital expenses for the companies that employ them
and the added convenience of "house calls" for the
patients. Initially, TDS services will go live in
Texas. Discussions have commenced in other US states
and  TDST's nationwide roll-out program will
go into effect quickly.

Analyst Conclusion

The
recent SEC ruling to leave the Over The Counter Bulletin
Board in its current form is a very bullish sign for
this market - possibly a turning point. We think that
this is an encouraging signal from regulators that the
OTCBB can expect a more positive financial climate going
forward. We assessed TDST bearing these 3 basic
investment criteria in mind:

1. TDST is in a leading
Group.

Chart

2. The company financials are strong.

3. The overall market is in a confirmed rally.

I
would expect great things from this company and in my
opinion it is a Strong Buy.

Editing
Chairman

Click
Here to view our disclaimer or to change your email preferences.